Tomas B. Corcoran

Tomas B. Corcoran

Auto-generated profile, based on publicly available information

Tomas B. Corcoran

Department of Anaesthesia and Pain Medicine, Royal Perth Hospital, Perth, Australia

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
TCTomas Corcoran
Tomas Corcoran
JRJulia Emma Joy Rhodes
Julia Emma Joy Rhodes
SCSarah Clarke
Sarah Clarke
PMPaul S. Myles
Paul S. Myles
KHKwok-Ming Ho
Kwok-Ming Ho
Both “liberal” and “goal-directed” (GD) therapy use a large amount of perioperative fluid, but they appear to have very different effects on perioperative outcomes. We sought to determine whether one fluid management strategy was superior to the others. We selected randomized controlled trials (RCTs) on the use of GD or restrictive versus liberal fluid therapy (LVR) in major adult surgery from MEDLINE, EMBASE, PubMed (1951 to April 2011), and Cochrane controlled trials register without language restrictions. Indirect comparison between the GD and LVR strata was performed. A total of 3861 patients from 23 GD RCTs (median sample size = 90, interquartile range [IQR] 57 to 109) and 1160 patients from 12 LVR RCTs (median sample size = 80, IQR36 to 151) were considered. Both liberal and GD therapy used more fluid compared to their respective comparative arm, but their effects on outcomes were very different. Patients in the liberal group of the LVR stratum had a higher risk of pneumonia (risk ratio [RR] 2.2, 95% confidence interval [CI] 1.0 to 4.5), pulmonary edema (RR 3.8, 95% CI 1.1 to 13), and a longer hospital stay than those in the restrictive group (mean difference [MD] 2 days, 95% CI 0.5 to 3.4). Using GD therapy also resulted in a lower risk of pneumonia (RR 0.7, 95% CI 0.6 to 0.9) and renal complications (0.7, 95% CI 0.5 to 0.9), and a shorter length of hospital stay (MD 2 days, 95% CI 1 to 3) compared to not using GD therapy. Liberal fluid therapy was associated with an increased length of hospital stay (4 days, 95% CI 3.4 to 4.4), time to first bowel movement (2 days, 95% CI 1.3 to 2.3), and risk of pneumonia (RR ratio 3, 95% CI 1.8 to 4.8) compared to GD therapy. Perioperative outcomes favored a GD therapy rather than liberal fluid therapy without hemodynamic goals. Whether GD therapy is superior to a restrictive fluid strategy remains uncertain.

6 May 2021 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
TCTomás B. Corcoran
Tomás B. Corcoran
PMPaul S. Myles
Paul S. Myles
AFAndrew B. Forbes
Andrew B. Forbes
ACAllen C. Cheng
Allen C. Cheng
LBLeon A. Bach
Leon A. Bach
KHKwok M. Ho
Kwok M. Ho
The glucocorticoid dexamethasone prevents nausea and vomiting after surgery, but there is concern that it may increase the risk of surgical-site infection. In this pragmatic, international, noninferiority trial, we randomly assigned 8880 adult patients who were undergoing nonurgent, noncardiac surgery of at least 2 hours’ duration, with a skin incision length longer than 5 cm and a postoperative overnight hospital stay, to receive 8 mg of intravenous dexamethasone or matching placebo while under anesthesia. Randomization was stratified according to diabetes status and trial center. The primary outcome was surgical-site infection within 30 days after surgery. The prespecified noninferiority margin was 2.0 percentage points. A total of 8725 participants were included in the modified intention-to-treat population (4372 in the dexamethasone group and 4353 in the placebo group), of whom 13.2% (576 in the dexamethasone group and 572 in the placebo group) had diabetes mellitus. Of the 8678 patients included in the primary analysis, surgical-site infection occurred in 8.1% (354 of 4350 patients) assigned to dexamethasone and in 9.1% (394 of 4328) assigned to placebo (risk difference adjusted for diabetes status, −0.9 percentage points; 95.6% confidence interval [CI], −2.1 to 0.3; P<0.001 for noninferiority). The results for superficial, deep, and organ-space surgical-site infections and in patients with diabetes were similar to those of the primary analysis. Postoperative nausea and vomiting in the first 24 hours after surgery occurred in 42.2% of patients in the dexamethasone group and in 53.9% in the placebo group (risk ratio, 0.78; 95% CI, 0.75 to 0.82). Hyperglycemic events in patients without diabetes occurred in 22 of 3787 (0.6%) in the dexamethasone group and in 6 of 3776 (0.2%) in the placebo group. Dexamethasone was noninferior to placebo with respect to the incidence of surgical-site infection within 30 days after nonurgent, noncardiac surgery. (Funded by the Australian National Health and Medical Research Council and others; PADDI Australian New Zealand Clinical Trials Registry number, ACTRN12614001226695.)

29 October 2022 in Anaesthesia
Verified
Journal Article
Open access
CBC. R. Bain
C. R. Bain
PMP. S. Myles
P. S. Myles
TCT. Corcoran
T. Corcoran
JDJ. M. Dieleman
J. M. Dieleman
Summary: In some patients, the inflammatory‐immune response to surgical injury progresses to a harmful, dysregulated state. We posit that postoperative systemic inflammatory dysregulation forms part of a pathophysiological response to surgical injury that places patients at increased risk of complications and subsequently prolongs hospital stay. In this narrative review, we have outlined the evolution, measurement and prediction of postoperative systemic inflammatory dysregulation, distinguishing it from a healthy and self‐limiting host response. We reviewed the actions of glucocorticoids and the potential for heterogeneous responses to peri‐operative corticosteroid supplementation. We have then appraised the evidence highlighting the safety of corticosteroid supplementation, and the potential benefits of high/repeated doses to reduce the risks of major complications and death. Finally, we addressed how clinical trials in the future should target patients at higher risk of peri‐operative inflammatory complications, whereby corticosteroid regimes should be tailored to modify not only the a priori risk, but also further adjusted in response to markers of an evolving pathophysiological response.

9 October 2006 in British Journal of Anaesthesia
Verified
Journal Article
Open access
PDF file
TCT.B. Corcoran
T.B. Corcoran
AEA. Engel
A. Engel
HSH. Sakamoto
H. Sakamoto
AOA. O'Shea
A. O'Shea
SOS. O'Callaghan-Enright
S. O'Callaghan-Enright
GSG. D. Shorten
G. D. Shorten
Background. Coronary artery bypass grafting (CABG) with cardiopulmonary bypass elicits a potent reperfusion injury and inflammatory response, more intense in patients with impaired myocardial function. Propofol has antioxidant properties which may attenuate such a response. Methods. In total, 27 patients with impaired left ventricular function undergoing CABG were randomly allocated to receive either target-controlled infusion propofol (P) or saline (S) immediately before aortic cross-clamp release until 4 h after reperfusion. Troponin-I, Urinary 8-epi PGF-2α isoprostane, coronary sinus and systemic malondialdehyde concentrations, Interleukin-6 (IL-6), -8 and -10 concentrations and leucocytes function studies (neutrophil respiratory burst, phagocytosis, CD-11b and CD-18 expression) were measured. Results. Propofol decreased MDA coronary sinus concentration at 1, 3 and 5 min after reperfusion (P<0.01); 60 min after reperfusion a significant difference between the two groups in systemic MDA concentrations was also seen. IL-6 concentration increases were significantly greater in Group S than Group P, 4 h after reperfusion [1118 (1333) pg ml−1vs 228 (105) pg ml−1, P<0.01]. Serum IL-8 concentrations did not increase significantly in either group. Compared with baseline values IL-10 concentrations decreased after reperfusion but the values were higher in the propofol group than in the control group [22 (16) vs 11 (4) pg ml−1, P<0.05]. No difference in leucocyte function or urinary isoprostane concentrations was demonstrated. Conclusion. Propofol attenuates free-radical-mediated lipid peroxidation and systemic inflammation in patients with impaired myocardial function undergoing CABG.

1 September 2009 in The Clinical Journal of Pain
Verified
Journal Article
Closed access
TCTomás B. Mb Corcoran
Tomás B. Mb Corcoran
FHFran Bsc Haigh
Fran Bsc Haigh
ASAmanda Seabrook
Amanda Seabrook
SSStephan A. Schug
Stephan A. Schug
Background The Internet is an increasingly popular information resource for patients. Patients with chronic pain are a subsection of the community who are likely to seek information about their condition, but previously little was known about the quality of information they may encounter during an Internet search. Aims The aims of this study were to develop and validate a scoring system for assessing chronic pain websites and then use this to determine the quality of chronic pain information on the Internet, which a patient employing typical “surfer” behavior might encounter. Methods A scoring system for assessing chronic pain websites was designed and validated. It comprised quality (design features) and technical (information) accuracy scores. Validity was assessed by intraclass correlation coefficients. The search term “chronic pain” was used on 5 popular search engines to identify websites. Only the first 10 sites retrieved were scored. Results There were 23 websites duplicated across the search engines, leaving a total of 27 websites to be scored. The majority of websites were rated as either poor or fair across the 2 individual scores and the grand score. Two websites had a grand score classified as either very good or excellent. Conclusions Although we cannot determine whether patients accurately interpret the quality of websites, our study confirms that good quality information about chronic pain is unlikely to be retrieved by our patients on the Internet.

1 February 2017 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
TCT Corcoran
T Corcoran
JKJ Kasza
J Kasza
TST.G. Short
T.G. Short
EOE O'Loughlin
E O'Loughlin
MCMatthew TV Chan
Matthew TV Chan
PMP Myles
P Myles
In a post hoc analysis of the ENIGMA-II trial, we sought to determine whether intraoperative dexamethasone was associated with adverse safety outcomes. Inverse probability weighting with estimated propensity scores was used to determine the association of dexamethasone administration with postoperative infection, quality of recovery, and adverse safety outcomes for 5499 of the 7112 non-cardiac surgery subjects enrolled in ENIGMA-II. Dexamethasone was administered to 2178 (40%) of the 5499 subjects included in this analysis and was not associated with wound infection [189 (8.7%) vs 275 (8.3%); propensity score-adjusted relative risk (RR) 1.10; 95% confidence interval (CI) 0.89-1.34; P=0.38], severe postoperative nausea and vomiting on day 1 [242 (7.3%) vs 189 (8.7%); propensity score-adjusted RR 1.06; 95% CI 0.86-1.30; P=0.59], quality of recovery score [median 14, interquartile range (IQR) 12-15, vs median 14, IQR 12-16, P=0.10), length of stay in the postanaesthesia care unit [propensity score-adjusted median (IQR) 2.0 (1.3, 2.9) vs 1.9 (1.3, 3.1), P=0.60], or the primary outcome of the main trial. Dexamethasone administration was associated with a decrease in fever on days 1-3 [182 (8.4%) vs 488 (14.7%); RR 0.61; 95% CI 0.5-0.74; P<0.001] and shorter lengths of stay in hospital [propensity score-adjusted median (IQR) 5.0 (2.9, 8.2) vs 5.3 (3.1, 9.1), P<0.001]. Neither diabetes mellitus nor surgical wound contamination status altered these outcomes. Dexamethasone administration to high-risk non-cardiac surgical patients did not increase the risk of postoperative wound infection or other adverse events up to day 30, and appears to be safe in patients either with or without diabetes mellitus. NCT00430989.